Sorry, you need to enable JavaScript to visit this website.

Pfizer Provides Update on U.S. Regulatory Review of TALZENNA in Combination with XTANDI for Broader Use in Metastatic Castration-Resistant Prostate Cancer

New York, June 13, 2025 – Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration’s (FDA) decision on the supplemental New Drug Application (sNDA) for TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) for men with metastatic castration-resistant prostate cancer (mCRPC).

Pfizer and BioNTech Submit EMA Application for COVID-19 Vaccine Targeting LP.8.1 for 2025-2026 Season

NEW YORK and MAINZ, GERMANY, MAY 28, 2025 -- Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that they have submitted a regulatory application to the European Medicines Agency (EMA) for approval of COMIRNATY® for the 2025-2026 season, targeting the LP.8.1 strain.

Pfizer Announces New Chief Internal Medicine Officer

New York, March 6, 2025 – Pfizer Inc. (NYSE: PFE) today announced that James List, M.D., Ph.D., has joined the company as Chief Internal Medicine Officer. In this role, Dr. List will oversee Pfizer’s Internal Medicine portfolio, from early discovery to late development, inclusive of Medical Affairs and Business Development strategies. He will be responsible for advancing Pfizer’s emerging pipeline of cardiovascular, metabolic, hematologic, and obesity medicines.

Pfizer’s ABRYSVO® Receives Positive CHMP Opinion for Adults Aged 18 to 59

NEW YORK, March 3, 2025 – Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for ABRYSVO® (Respiratory Syncytial Virus Vaccine), the company’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age.

Pfizer Announces New Chief Medical Officer

Pfizer Inc. (NYSE: PFE) Patrizia Cavazzoni, M.D. will rejoin the company as Chief Medical Officer, Executive Vice President. In this role, Dr. Cavazzoni will lead Pfizer’s regulatory, pharmacovigilance, safety, epidemiology, and medical information and evidence generation, among other medical functions, and will report to Chris Boshoff, M.D., Ph.D., Chief Scientific Officer and President, Pfizer Research & Development. Dr. Cavazzoni will succeed Aida Habtezion, M.D., MSc, FRCPC, AGAF who will be leaving Pfizer to pursue other opportunities.

Pfizer Announces New Chief Oncology Officer

New York, February 5, 2025 – Pfizer Inc. (NYSE: PFE) today announced that Jeffrey Legos, PhD, MBA, will join the company as Chief Oncology Officer. In this role, Dr. Legos will be responsible for leading the company’s Oncology Research & Development, overseeing all functions from pre-clinical to late-stage clinical development activities. Dr. Legos will report to Chris Boshoff, M.D., PhD, Chief Scientific Officer and President, Pfizer Research & Development, and will represent Oncology on Pfizer’s R&D Leadership Team. Dr.

The Pfizer Foundation Provides $15 Million Investment to Improve Breast Cancer Care in Sub-Saharan Africa

NEW YORK, January 17, 2025 – The Pfizer Foundation today progressed a three-year $15 million initiative to help improve the lives of women with breast cancer in Rwanda, Ghana, and Tanzania. Grant funding will be provided to global health nonprofit organizations, Jhpiego and Partners In Health, to support and scale community- and country-led efforts—developed in collaboration with ministries of health—addressing barriers to timely breast cancer diagnosis, treatment, and care in these countries.

Pfizer Receives Positive CHMP Opinion for its Treatment for Adults and Adolescents with Hemophilia A and B

  • If approved in Europe, marstacimab is expected to become the first once-weekly subcutaneous treatment for people living with severe hemophilia B and the first to be administered via a pre-filled pen for people living with severe hemophilia A or B

NEW YORK, September 20, 2024 – Pfizer Inc.

Pfizer Statement on Publication of ELIQUIS® Maximum Fair Price

NEW YORK, August 15, 2024 — Pfizer Inc. (NYSE: PFE) today announced that on August 15, 2024, the U.S. Department of Health and Human Services released the “maximum fair price” (MFP) for ELIQUIS® (apixaban), which was selected in the first round of government price setting as part of the Inflation Reduction Act (IRA). The imposed MFP for a 30-day equivalent supply of ELIQUIS, which is the price that Medicare will pay for ELIQUIS as of January 1, 2026, is $231.00.

Pfizer Receives Positive CHMP Opinion for its One-Time Gene Therapy for Adults with Hemophilia B

NEW YORK, May 31, 2024 – Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for fidanacogene elaparvovec, a gene therapy for the treatment of severe and moderately severe hemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors and without detectable antibodies to variant AAV serotype Rh74.

Subscribe to Updates